EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T‐cell redirecting immunotherapy

Aintzane Zabaleta iD, Noemi Puig, Maria-Teresa Cedena iD, Aina Oliver-Caldes, José J Perez, Cristina Moreno, Luis-Esteban Tamariz-Amador iD, Paula Rodriguez-Otero, Felipe Prosper, Veronica Gonzalez-Calle, Lucía López-Corral iD, Beatriz Rey-Búa und 14 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Aintzane Zabaleta und 25 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra …. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasm, Residual, Remission Induction, Immunotherapy, Adoptive. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIBER-Consorcio Centro de Investigación Biomédica en Red - Área de Oncología - Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria, (cofunded by the EU), Cancer Research UK (A26819), FCAECC and AIRC under the Accelerator Award Programme (EDITOR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The impact of measurable residual disease (MRD) in relapse/refractory multiple myeloma (RRMM) patients treated with T‐cell redirecting immunotherapy is uncertain. We analyzed MRD dynamics using next‐generation flow in 201 patients treated in clinical trials with chimeric antigen receptor (CAR) T cells and T‐cell engagers (TCE). Achieving MRD negativity at 10 −6 was associated with 89% reduction in the risk of progression and/or death. Survival outcomes were improved in patients with sustained versus transient MRD negativity and were dismal in those who remained MRD positive. The intent‐to‐treat MRD negative rates were higher in patients treated with CAR T cells versus TCE. However, among patients achieving MRD negativity, there were no differences in survival outcomes when stratified according to treatment with CAR T cells versus TCE. In multivariate analysis including the number of prior lines of treatment, International Staging System, cytogenetic risk, extramedullary disease and type of T‐cell redirecting immunotherapy, only the complete remission (CR) and MRD statuses showed independent prognostic value for progression‐free and overall survival. In conclusion, our study shows that deep and sustained MRD negative CR is the most relevant prognostic factor and should be considered as the treatment endpoint in RRMM patients treated with CAR T cells and TCE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaNeoplasm, ResidualRemission InductionImmunotherapy, AdoptiveHumansMaleFemaleMiddle AgedAgedT-LymphocytesRecurrenceAdultReceptors, Chimeric AntigenClinical Relevance

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
  • Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain.
  • Servicio de Hematología y Hemoterapia, Hospital 12 de Octubre, Madrid, Spain.
  • Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

ORCID-Profile: Aintzane Zabaleta, Maria-Teresa Cedena, Luis-Esteban Tamariz-Amador, Lucía López-Corral, José María Sánchez-Pina, Nieves López-Muñoz, Manel Juan, Joaquín Martinez-Lopez

Förderung

  • CIBER-Consorcio Centro de Investigación Biomédica en Red - Área de Oncología - Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación
  • Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria, (cofunded by the EU)
  • Cancer Research UK (A26819), FCAECC and AIRC under the Accelerator Award Programme (EDITOR)
  • Black Swan Research Initiative of the International Myeloma Foundation
  • CRIS Cancer Foundation
  • La Caixa Foundation
  • Fundación Científica Asociación Española Contra el Cáncer
  • Riney Family Multiple Myeloma Research Program

Zitieren

APA

Zabaleta, A., Puig, N., Cedena, M. T., Oliver-Caldes, A., Perez, J. J., Moreno, C., Tamariz-Amador, L. E., Rodriguez-Otero, P., Prosper, F., Gonzalez-Calle, V., López-Corral, L., Rey-Búa, B., Puertas, B., Mirás, F., Sánchez-Pina, J. M., López-Muñoz, N., Juan, M., González-Navarro, E. A., Urbano, Á., …, & Paiva, B. (2025). Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T‐cell redirecting immunotherapy. American Journal of Hematology. https://doi.org/10.1002/ajh.27526

Vancouver

Zabaleta A, Puig N, Cedena MT, Oliver-Caldes A, Perez JJ, Moreno C, et al. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T‐cell redirecting immunotherapy. American Journal of Hematology. 2025. doi:10.1002/ajh.27526

BibTeX
@article{Zabaleta2025,
  author = {Zabaleta, Aintzane and Puig, Noemi and Cedena, Maria-Teresa and Oliver-Caldes, Aina and Perez, José J and Moreno, Cristina and Tamariz-Amador, Luis-Esteban and Rodriguez-Otero, Paula and Prosper, Felipe and Gonzalez-Calle, Veronica and López-Corral, Lucía and Rey-Búa, Beatriz and Puertas, Borja and Mirás, Fátima and Sánchez-Pina, José María and López-Muñoz, Nieves and Juan, Manel and González-Navarro, E Azucena and Urbano, Álvaro and de Larrea, Carlos Fernández and Blade, Joan and Lahuerta, Juan-José and Martinez-Lopez, Joaquín and Mateos, Maria-Victoria and San Miguel, Jesús F and Paiva, Bruno},
  title = {Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T‐cell redirecting immunotherapy},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27526}
}
Kostenlos starten →